Handelsavisen
prelaunch
Companies Healthcare BMND.NLB
BM
BMND.NLB Biotechnology & Medical Research

Biomind Labs Inc

$0,23
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
11,4 %
Net margin
Debt / equity
-0,54
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Biomind Labs Inc has a highly leveraged capital structure, with total liabilities of $1.71 billion and total equity of -$1.64 billion, resulting in a debt-to-equity ratio of -0.54. The company's liquidity position is weak, as evidenced by a current ratio of 0.03, indicating that it has insufficient current assets to cover its short-term obligations. Operating cash flow is negative at -$115.44 million, and free cash flow is -$183.93 million, further highlighting the company's cash flow challenges. Profitability metrics are concerning, with a net loss of -$186.16 million and an operating loss of -$110.67 million. Return on equity is 11.38%, which is unusually high given the negative equity position, and return on assets is -2.54%, indicating poor asset utilization. These figures suggest the company is not generating sufficient returns to justify its capital structure or asset base. The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns implies a lack of diversification in its revenue streams. This could pose a risk if the company's primary market or product line experiences a downturn. Growth trajectory is no

Business. Biomind Labs Inc (BMND.NLB) is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, utilizing a product-sale revenue model. Specific details regarding operating segments, headquarters location, and primary exchange listings are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
11,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BMND.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BMND.NLB. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Biomind Labs Inc (BMND.NLB) is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, utilizing a product-sale revenue model. Specific details regarding operating segments, headquarters location, and primary exchange listings are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Biomind Labs Inc has a highly leveraged capital structure, with total liabilities of $1.71 billion and total equity of -$1.64 billion, resulting in a debt-to-equity ratio of -0.54. The company's liquidity position is weak, as evidenced by a current ratio of 0.03, indicating that it has insufficient current assets to cover its short-term obligations. Operating cash flow is negative at -$115.44 million, and free cash flow is -$183.93 million, further highlighting the company's cash flow challenges.

    Profitability metrics are concerning, with a net loss of -$186.16 million and an operating loss of -$110.67 million. Return on equity is 11.38%, which is unusually high given the negative equity position, and return on assets is -2.54%, indicating poor asset utilization. These figures suggest the company is not generating sufficient returns to justify its capital structure or asset base.

    The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns implies a lack of diversification in its revenue streams. This could pose a risk if the company's primary market or product line experiences a downturn.

    Growth trajectory is not clearly defined in the available data, but the company's negative operating and net income, combined with negative cash flows, suggest a lack of sustainable growth. The outlook for the current fiscal year is likely to remain challenging unless the company can significantly improve its operational performance or secure additional financing.

    Risk factors include liquidity constraints and the potential for further dilution if the company needs to raise additional capital. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's negative net cash position after subtracting total debt is a key flag. The company's reliance on external financing and its inability to generate positive cash flows increase the risk of financial distress.

    Recent events, including the latest financial filing, highlight the company's ongoing financial challenges. The absence of recent earnings call transcripts or significant news events suggests a lack of public communication about strategic initiatives or financial improvements.

    Key takeaways
    • Biomind Labs Inc is operating at a significant loss, with a net income of -$186.16 million and an operating loss of -$110.67 million.
    • The company's liquidity position is weak, with a current ratio of 0.03 and negative operating and free cash flows.
    • Return on equity is unusually high at 11.38%, but this is due to the negative equity position, and return on assets is -2.54%.
    • The company's capital structure is highly leveraged, with total liabilities of $1.71 billion and total equity of -$1.64 billion.
    • The company's financial health is at risk due to its negative net cash position after subtracting total debt.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    $0,23
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$1.6M
    Net cash
    -$883.4k
    Current ratio
    0.0
    Debt / equity
    -0.5
    ROA
    -2.5%
    ROE
    11.4%
    Cash conversion
    62.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    ROE11,4 %Above P75
    D/E-0,54Best in class
    Cash Conv0,62Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Biomind Labs Inc Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BMND.NLBCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage